Mucosal-associated invariant T (MAIT) cells have a well-defined protective role in bacterial infection, due to their rapid activation in response to small metabolite antigens derived from the riboflavin synthesis pathway, presented on MHC related protein MR1 (Reantragoon et. al., 2012). As well as their capacity for anti-microbial cytotoxicity and cytokine production (Rudak et. al. 2018), emerging functions have also been described for MAIT cells in homeostasis, tissue repair, cancer and autoimmunity (eg. Leng at. al. 2019).
A tissue-resident population of MAIT cells was recently identified in the brain and found to perform important homeostatic functions (Zhang et. al. 2022). Additionally, there is evidence indicating MAIT cell infiltration into brain tumours (Peterfalvi et. al. 2008). However, basic questions remain regarding MAIT cell responses to tumour cells, particularly within the tumour microenvironment prompting us to investigate the role of MAIT cells in brain cancer.
Using in vivo models of glioblastoma (GBM), we demonstrate that survival is reduced in MR1-/- mice, implying a protective role for MAIT cells in this context. Phenotypic analysis of tumour-infiltrating lymphocytes (TILs) indicates MAIT cells can be activated and produce cytokines in response to tumours. In vitro study of the antigen presentation capacity of the tumour cells shows GBM tumour cells are capable of presenting antigen to MAIT cells and initiating MR1-dependent activation. Further, we demonstrate successful in vivo MAIT cell expansion in the mouse brain and capacity to manipulate the phenotype of expanded MAIT cells, indicating the potential of MAIT cell-based immunotherapy. Future directions for this work include detailed study of expanded MAIT cell function and phenotype following in vivo tumour challenge, including the MR1 dependence of their response.